메뉴 건너뛰기




Volumn 4, Issue 2, 2001, Pages 189-196

Recent advances in 5-HT1D-selective agonists

Author keywords

[No Author keywords available]

Indexed keywords


EID: 0141712033     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article
Times cited : (7)

References (41)
  • 2
    • 0032970989 scopus 로고    scopus 로고
    • A review of central 5-HT receptors and their function
    • Bames NM, Sharp T: A review of central 5-HT receptors and their function. Neuropharmacology (1999) 38:1083-1152. This is an excellent review of the various serotanin receptor subtypes, highlighting their distribution and functional significance of each subtype reported to date.
    • (1999) Neuropharmacology , vol.38 , pp. 1083-1152
    • Bames, N.M.1    Sharp, T.2
  • 4
    • 0024538938 scopus 로고
    • Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain
    • Hoyer D, Middlemiss DN: Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain. Trends PharmacolSci(1989) 10:130-132.
    • (1989) Trends PharmacolSci , vol.10 , pp. 130-132
    • Hoyer, D.1    Middlemiss, D.N.2
  • 7
    • 0034157403 scopus 로고    scopus 로고
    • Millson DS, Tepper SJ, Rapoport AM: Migraine pharmacotherapy with oral triptans: a rational approach to clinical management Exp Opin Pharmacother(2000) 1(3):391-404. An excellent review of the pharmacodynamic (5-HTw agonism) and pharmacokinetic properties of currently marketed triptans which correlates these properties to their clinical efficacy in the management of migraine.
    • (2000) Exp Opin Pharmacother , vol.1 , Issue.3 , pp. 391-404
  • 8
    • 0034157403 scopus 로고    scopus 로고
    • Migraine pharmacotherapy with oral triptans a rational approach to clinical management
    • Millson DS, Tepper SJ, Rapoport AM: Migraine pharmacotherapy with oral triptans: a rational approach to clinical management Exp Opin Pharmacother(2000) 1(3):391-404. An excellent review of the pharmacodynamic (5-HTw agonism) and pharmacokinetic properties of currently marketed triptans which correlates these properties to their clinical efficacy in the management of migraine.
    • (2000) Exp Opin Pharmacother , vol.1 , Issue.3 , pp. 391-404
    • Millson, D.S.1    Tepper, S.J.2    Rapoport, A.M.3
  • 9
    • 0031771420 scopus 로고
    • 1B/1D receptor agonists in migraine
    • 1B/1D receptor agonists in migraine. CNS Drugs (1989) 10:271 -286.
    • (1989) CNS Drugs , vol.10 , pp. 271-286
    • Goadsby, P.J.1
  • 10
    • 0030914002 scopus 로고    scopus 로고
    • Rizatriptan has central antinociceptive effects against durally evoked responses
    • Cumberbatch MJ, Hill R, Hargreaves RJ: Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol(1997) 328:37-40.
    • (1997) Eur J Pharmacol , vol.328 , pp. 37-40
    • Cumberbatch, M.J.1    Hill, R.2    Hargreaves, R.J.3
  • 11
    • 0027509161 scopus 로고
    • The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in human and cats
    • Goadsby PJ, Edvinsson L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in human and cats. Ann Weura(1993) 33:48-56.
    • (1993) Ann Weura , vol.33 , pp. 48-56
    • Goadsby, P.J.1    Edvinsson, L.2
  • 12
    • 0030902898 scopus 로고    scopus 로고
    • The novel antimigraine agent rizatriptan inhibits neurogenic durai vasodiiation and extravasation
    • Williamson DJ, Shepheard SL, Hill RG, Hargreaves RJ: The novel antimigraine agent rizatriptan inhibits neurogenic durai vasodiiation and extravasation. EurJ Pharmacol (1997) 328:61 -64.
    • (1997) EurJ Pharmacol , vol.328 , pp. 61-64
    • Williamson, D.J.1    Shepheard, S.L.2    Hill, R.G.3    Hargreaves, R.J.4
  • 13
    • 0030977313 scopus 로고    scopus 로고
    • Sumatriptan inhibits neurogenic vasodilation of durai blood vessels in the anaesthetized rat - Intravital microscope studies
    • Wilüamson DJ, Hargreaves RJ, Hill RG, Shepheard SL: Sumatriptan inhibits neurogenic vasodilation of durai blood vessels in the anaesthetized rat - Intravital microscope studies. Cephalagia (1997) 17:525-531.
    • (1997) Cephalagia , vol.17 , pp. 525-531
    • Wilüamson, D.J.1    Hargreaves, R.J.2    Hill, R.G.3    Shepheard, S.L.4
  • 14
    • 0027223875 scopus 로고
    • Expression of mRNA for the serotonin 5-hydroxytryptamine 1D receptor subtype in human and bovine cerebral arteries
    • Hamel E, Fan E, LJnvilie D, Ting V, Villemure JG, Chia LS: Expression of mRNA for the serotonin 5-hydroxytryptamine 1D receptor subtype in human and bovine cerebral arteries. Mol Pharmacol (1993)44242-246.
    • (1993) Mol Pharmacol , pp. 44242-44246
    • Hamel, E.1    Fan, E.2    Ljnvilie, D.3    Ting, V.4    Villemure, J.G.5    Chia, L.S.6
  • 15
    • 0028175755 scopus 로고
    • Selective 5-HT,0 ' serotonin receptor gene expression in trkjeminal ganglia: Implications for antimigraine drug development
    • Rebeck GW, Maynard Kl, Hyman BT, Moskowitz MA: Selective 5-HT,0 ' serotonin receptor gene expression in trkjeminal ganglia: implications for antimigraine drug development. Proc NatlAcad Sei USA (1994) 91:3666-3669.
    • (1994) Proc NatlAcad Sei USA , vol.91 , pp. 3666-3669
    • Rebeck, G.W.1    Maynard, K.I.2    Hyman, B.T.3    Moskowitz, M.A.4
  • 16
    • 0029813854 scopus 로고    scopus 로고
    • Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels
    • Bouchelet I, Cohen Z, Case B, Seguela P, Hamel : Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol (1996) 50:219-223.
    • (1996) Mol Pharmacol , vol.50 , pp. 219-223
    • Bouchelet, I.1    Cohen, Z.2    Case, B.3    Seguela, P.4    Hamel5
  • 17
    • 0031283073 scopus 로고    scopus 로고
    • Differential distribution of 5HT,immunoreactivity within the human trigemino-cerebrovascular system Implications for the discovery of new antimigraine drugs
    • Longmore J, Shaw D, Smith D, Hopkins R, McAIster G, Pickard JD, Sirinathsinghji DRD, Butler AJ, Hill R: Differential distribution of 5HT,immunoreactivity within the human trigemino-cerebrovascular system: Implications for the discovery of new antimigraine drugs. Cephalagia (1997)17:833-842.
    • (1997) Cephalagia , pp. 17833-17842
    • Longmore, J.1    Shaw, D.2    Smith, D.3    Hopkins, R.4    McAister, G.5    Pickard, J.D.6    Sirinathsinghji, D.R.D.7    Butler, A.J.8    Hill, R.9
  • 18
    • 0028816276 scopus 로고
    • Cardiovascular adverse reactions to sumatriptan. Cause for Concern?
    • Ottervanger JP, Stricker BH: Cardiovascular adverse reactions to sumatriptan. Cause for Concern? CNS Drugs (1995) 3:90-98.
    • (1995) CNS Drugs , vol.3 , pp. 90-98
    • Ottervanger, J.P.1    Stricker, B.H.2
  • 19
    • 0032780399 scopus 로고    scopus 로고
    • Structure-activity relationships and pharmacological profiles of new 5-HT, receptor agonists as antimigraine agents
    • Perez M, John GW: Structure-activity relationships and pharmacological profiles of new 5-HT, receptor agonists as antimigraine agents. CurrOpin Drug Discovery Dev(1999) 2:304-310. A concise but comprehensive review highlighting the pharmacological properties of recently developed 5-HT,a agonists (both selective and nonselective) with particular emphasis on a class of non-selective ligands showing some degree of tissue selectivity.
    • (1999) CurrOpin Drug Discovery Dev , vol.2 , pp. 304-310
    • Perez, M.1    John, G.W.2
  • 20
    • 0032897777 scopus 로고    scopus 로고
    • Recent developments in 5-HT1D agonists
    • Russell MGN: Recent developments in 5-HT1D agonists. IDrugs (1999)2:37-43.
    • (1999) IDrugs , vol.2 , pp. 37-43
    • Russell, M.G.N.1
  • 22
    • 0030669050 scopus 로고    scopus 로고
    • MacLeod AM, Street LJ, Reeve AJ, Jelly RA, Stemfeld F, Beer MS, Stanton JA, Watt AP, Rathbone D, Matassa VG: Selective, orally active 5-HT1D receptor agonists as potential antimigraine agents. J Med Chem (1997) 40:3501 -3503.
    • (1997) J Med Chem , vol.40 , pp. 3501-3503
  • 24
    • 0031857819 scopus 로고    scopus 로고
    • Enhancement of oral absorption in selective 5-HT, receptor agonists: Fluorinated 3-[3-{piperidin-1-ylpropyl]indoles
    • Castro JL, Collins I, Russell GNM, Watt AP, Sohal B, Rathbone D, Beer MS, Stanton JA: Enhancement of oral absorption in selective 5-HT, receptor agonists: fluorinated 3-[3-{piperidin-1-yl)propyl]indoles. J Med Chem (1998) 41:2667-2670.
    • (1998) J Med Chem , vol.41 , pp. 2667-2670
    • Castro, J.L.1    Collins, I.2    Gnm, R.3    Watt, A.P.4    Sohal, B.5    Rathbone, D.6    Beer, M.S.7    Stanton, J.A.8
  • 26
    • 0033530881 scopus 로고    scopus 로고
    • Bourrain S, Neduvelil JG, Beer MS, Stanton JA, Showll GA, MacLeod AM: 4-Hydroxy-1-{3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyr| piperidines: selective h5-HTc agonists for the treatment of migraine. Bioorg Med Chem Lett (1999) 9:3369-3374.
    • (1999) Bioorg Med Chem Lett , vol.9 , pp. 3369-3374
  • 27
    • 0033530881 scopus 로고    scopus 로고
    • 4-Hydroxy-1-{3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyr| piperidines: Selective h5-HTc agonists for the treatment of migraine
    • Bourrain S, Neduvelil JG, Beer MS, Stanton JA, Showll GA, MacLeod AM: 4-Hydroxy-1-{3-(5-(1,2,4-triazol-4-yl)-1H-indol-3-yl)propyr| piperidines: selective h5-HTc agonists for the treatment of migraine. Bioorg Med Chem Lett (1999) 9:3369-3374.
    • (1999) Bioorg Med Chem Lett , vol.9 , pp. 3369-3374
    • Bourrain, S.1    Neduvelil, J.G.2    Beer, M.S.3    Stanton, J.A.4    Showll, G.A.5    MacLeod, A.M.6
  • 31
    • 0033494873 scopus 로고    scopus 로고
    • 1B/1D receptor agonists: Potential treatments for migraine. Med Chem Res (1999) 9:668-674.
    • (1999) Med Chem Res , vol.9 , pp. 668-674


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.